DWP16001 not checked
Daewoong Pharmaceutical Co. LTD.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Type 2 Diabetic Nephropathy, T2DM (Type 2 Diabetes Mellitus)
- Main trialPhase 3
- “This study aims to evaluate the efficacy and safety of DWP16001 in type 2 diabetic nephropathy with moderate renal impairment patients (CKD stage 3)”In the company’s words, NCT06606093 on ClinicalTrials.gov
Other drugs for T2DM (Type 2 Diabetes Mellitus)
- BR1019Boryung Pharmaceutical Co., Ltd · Phase 3
- CagriSemaNovo Nordisk · Phase 3
- QLG1091Qilu Pharmaceutical · Phase 3
- SHR-3167Hengrui · Phase 3
- Maridebart cafraglutideAmgen · Phase 3
- LenbelintideAstraZeneca · Phase 3
Coming up1
- Nov 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials20
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 1 Sep 2026 | Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients | |
| Phase 3Not yet recruiting | Nov 2027 | To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus | |
| Phase 3Completed | 25 Nov 2021 | The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus. | |
| Phase 3Completed | 17 Dec 2021 | The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes Mellitus | |
| Phase 3Completed | 16 May 2022 | Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin | |
| Phase 3Completed | 31 May 2022 | Study to Evaluate the Long Term Safety and Efficacy of DWP16001 Compared to Placebo in the Treatment of T2DM. | |
| Phase 3Unknown | 26 Feb 2024 | The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin | |
| Phase 3Unknown | 30 Sep 2024 | A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus | |
| Phase 3Unknown | Sep 2025 | Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus | |
| Phase 1Completed | 1 Aug 2021 | Pharmacokinetics and Safety Following Administration of DWP16001 | |
| Phase 1Unknown | 8 Apr 2022 | Study to Evaluate the Safety and PK Properties of DWP16001 in Healthy Subjects With Various Ethnicities | |
| Phase 1Completed | 24 May 2022 | A Crossover Study of DWJ1525 to Evaluate the Safety and Pharmacokinetic Properties in Healthy Volunteers | |
| Phase 1Completed | 16 Aug 2022 | Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics of DWP16001 Drug A and C | |
| Phase 1Unknown | Aug 2022 | The Drug Interaction of DWP16001 and DWC202010 After Oral Administration in Healthy Adults | |
| Phase 1Unknown | 31 Oct 2022 | Drug-Drug Interaction of DWP16001 in Combination With DWC202204 and DWC202205 in Healthy Male Adults | |
| Phase 1Unknown | 31 Mar 2023 | To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose Combination | |
| Phase 1Unknown | 31 May 2023 | To Evaluate the Effect of Food on the Safety and PK Characteristics of DWP16001 in Healthy Adult Volunteers | |
| Phase 1Unknown | 30 Apr 2024 | To Compare the Safety and PK/PD Characteristics of Subjects With Between Hepatic Impairment and Normal Hepatic Function | |
| Phase 1Unknown | 3 Dec 2024 | Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults | |
| Phase 1Completed | 7 Jan 2026 | Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026